Legal & General Group Plc Acquires 3,601 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Legal & General Group Plc boosted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 22.1% in the fourth quarter, HoldingsChannel reports. The firm owned 19,899 shares of the company’s stock after purchasing an additional 3,601 shares during the period. Legal & General Group Plc’s holdings in Entrada Therapeutics were worth $344,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after acquiring an additional 30,585 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Entrada Therapeutics by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after acquiring an additional 46,512 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Entrada Therapeutics by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after acquiring an additional 4,291 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Entrada Therapeutics in the 4th quarter valued at $137,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Entrada Therapeutics by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock valued at $3,408,000 after acquiring an additional 11,143 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Monday, March 31st.

Entrada Therapeutics Trading Up 2.1 %

Shares of TRDA stock opened at $9.13 on Thursday. The firm has a market capitalization of $346.51 million, a PE ratio of 5.74 and a beta of 0.04. The firm has a fifty day simple moving average of $9.61 and a two-hundred day simple moving average of $14.18. Entrada Therapeutics, Inc. has a 12 month low of $7.10 and a 12 month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.69. The business had revenue of $12.25 million during the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. On average, equities analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.